Closed Loop Medicine
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Closed Loop Medicine is a biotechnology research company based in Babraham, England, United Kingdom, with 11-50 employees. The company develops combination prescription drug and software products and operates a proprietary technology platform that enables personalized drug dose optimization by integrating medicines, software, and patient-led digital experiences within closed-loop models of care. Its objective is to advance precision care for all, focusing on individualized treatment approaches for patients with chronic diseases and aims to improve access and outcomes. In September 2025, Closed Loop Medicine announced the launch of a GLP-1 dosing platform in the United States, described as its first personalized GLP-1 dosing platform in that market. The company has seen leadership changes in recent years, including Kate Woolland appointed Chief Executive Officer in May 2025, Luba Greenwood named Chair of the Board in September 2024, and Konstantinos Vlassis appointed Chief Technology Officer in October 2023.